The DOI matches its Crossref record.
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Abstract
PURPOSE: To improve the prognosis of patients with poor-risk peripheral primitive neuroectodermal tumors (pPNETs; including peripheral neuroepithelioma and Ewing's sarcoma), while testing the feasibility of intensive use in adolescents and young adults of high-dose cyclophosphamide, doxorubicin, and vincristine (HD-CAV). PATIENTS AND METHODS: This report concerns previously untreated patients with newly diagnosed pPNET deemed poor-risk because of a tumor volume more than 100 cm3 or metastases to bone or bone marrow. The P6 protocol consists of seven courses of chemotherapy. Courses 1, 2, 3, and 6 include 6-hour infusions of cyclophosphamide on days 1 and 2 for a total of 4,200 mg/m2 per course (140 mg/kg per course for patients < 10 years old), plus 72-hour infusions of doxorubicin 75 mg/m2 and vincristine 2.0 mg/m2 beginning on day 1 (HD-CAV). Courses 4, 5, and 7 consist of 1-hour infusions of ifosfamide 1.8 g/m2/d and etoposide (VP-16) 100 mg/m2/d, for 5 days. Granulocyte colony-stimulating factor (G-CSF) and mesna are used. Courses start after neutrophil counts reach 500/microL and platelet counts reach 100,000/uL. Surgical resection follows course 3 and radiotherapy follows completion of all chemotherapy. RESULTS: Among the first 36 consecutive assessable patients (median age, 17 years), HD-CAV achieved excellent histopathologic or clinical responses in 34 patients and partial responses (PRs) in two patients. For 24 patients with locoregional disease, the 2-year event-free survival rate was 77%; adverse events were two locoregional relapses, one distant relapse, and one secondary leukemia. All six patients with metastatic disease limited to lungs achieved a complete response (CR) and did not relapse; one is in remission 36+ months from diagnosis, but the other patients are not assessable in terms of long-term efficacy of the P6 protocol because of short follow-up time (n = 3), additional systemic therapy (bone marrow transplantation), or septic death (autopsy showed no residual pPNET). All six patients with widespread metastases had major responses, including eradication of extensive bone marrow involvement, but distant relapses ensued. Myelosuppression was severe, but most patients received the first three courses of HD-CAV within 6 to 7 weeks. Major nonhematologic toxicities were mucositis and peripheral neuropathy. CONCLUSION: Excellent antitumor efficacy and manageable toxicity support the dose-intensive use of HD-CAV for pPNET in children, as well as in young adults. Consolidation of remissions of pPNET metastatic to bone and bone marrow remains a therapeutic challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657
Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial
Ladenstein, R., Pötschger, U., Le Deley, M. C., Whelan, J., Paulussen, M., Oberlin, O., van den Berg, H., Dirksen, U., Hjorth, L., Michon, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9864 · Cited by 540
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
de Alava, E., Kawai, A., Healey, J. H., Fligman, I., Meyers, P. A., Huvos, A. G., Gerald, W. L., Jhanwar, S. C., Argani, P., Antonescu, C. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1248 · Cited by 524
Self-citationEwing's Sarcoma Family of Tumors: Current Management
Bernstein, M., Kovar, H., Paulussen, M., Randall, R. L., Schuck, A., Teot, L. A., & Juergensg, H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-5-503 · Cited by 520
Motzer, R. J., Amsterdam, A., Prieto, V., Sheinfeld, J., Murty, V. V. V. S., Mazumdar, M., Bosl, G. J., Chaganti, R. S. K., & Reuter, V. E. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)64035-7 · Cited by 431
Metadata
- Authors
- Kushner, B. H., Meyers, P. A., Gerald, W. L., Healey, J. H., La Quaglia, M. P., Boland, P., Wollner, N., Casper, E. S., Aledo, A., & Heller, G.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-11
- Volume
- 13
- Issue
- 11
- Pages
- 2796-2804
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1925278504
- Cited by
- 163
- References
- 0
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. https://app.cochat.ai/papers/10.1200/jco.1995.13.11.2796
- The paper
- Kushner, B. H., Meyers, P. A., Gerald, W. L., Healey, J. H., La Quaglia, M. P., Boland, P., Wollner, N., Casper, E. S., Aledo, A., & Heller, G. (1995). Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1995.13.11.2796
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.